167 related articles for article (PubMed ID: 22879949)
1. Understanding the basis of drug resistance of the mutants of αβ-tubulin dimer via molecular dynamics simulations.
Natarajan K; Senapati S
PLoS One; 2012; 7(8):e42351. PubMed ID: 22879949
[TBL] [Abstract][Full Text] [Related]
2. Structural basis for drug resistance conferred by β-tubulin mutations: a molecular modeling study on native and mutated tubulin complexes with epothilone B.
Navarrete KR; Alderete JB; Jiménez VA
J Biomol Struct Dyn; 2015; 33(12):2530-40. PubMed ID: 26081685
[TBL] [Abstract][Full Text] [Related]
3. Structural insight into the mechanism of epothilone A bound to beta-tubulin and its mutants at Arg282Gln and Thr274Ile.
Shi G; Wang Y; Jin Y; Chi S; Shi Q; Ge M; Wang S; Zhang X; Xu S
J Biomol Struct Dyn; 2012; 30(5):559-73. PubMed ID: 22731768
[TBL] [Abstract][Full Text] [Related]
4. Comparative binding energy (COMBINE) analysis supports a proposal for the binding mode of epothilones to β-tubulin.
Coderch C; Klett J; Morreale A; Fernando Díaz J; Gago F
ChemMedChem; 2012 May; 7(5):836-43. PubMed ID: 22431398
[TBL] [Abstract][Full Text] [Related]
5. Molecular modeling study on the tubulin-binding modes of epothilone derivatives: Insight into the structural basis for epothilones activity.
Jiménez VA; Alderete JB; Navarrete KR
Chem Biol Drug Des; 2017 Dec; 90(6):1247-1259. PubMed ID: 28632973
[TBL] [Abstract][Full Text] [Related]
6. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells.
Giannakakou P; Gussio R; Nogales E; Downing KH; Zaharevitz D; Bollbuck B; Poy G; Sackett D; Nicolaou KC; Fojo T
Proc Natl Acad Sci U S A; 2000 Mar; 97(6):2904-9. PubMed ID: 10688884
[TBL] [Abstract][Full Text] [Related]
7. Molecular dynamics simulation and free energy landscape methods in probing L215H, L217R and L225M βI-tubulin mutations causing paclitaxel resistance in cancer cells.
Tripathi S; Srivastava G; Sharma A
Biochem Biophys Res Commun; 2016 Aug; 476(4):273-279. PubMed ID: 27233604
[TBL] [Abstract][Full Text] [Related]
8. Much anticipated--the bioactive conformation of epothilone and its binding to tubulin.
Heinz DW; Schubert WD; Höfle G
Angew Chem Int Ed Engl; 2005 Feb; 44(9):1298-301. PubMed ID: 15714588
[No Abstract] [Full Text] [Related]
9. The binding mode of epothilone A on alpha,beta-tubulin by electron crystallography.
Nettles JH; Li H; Cornett B; Krahn JM; Snyder JP; Downing KH
Science; 2004 Aug; 305(5685):866-9. PubMed ID: 15297674
[TBL] [Abstract][Full Text] [Related]
10. The betaI/betaIII-tubulin isoforms and their complexes with antimitotic agents. Docking and molecular dynamics studies.
Magnani M; Ortuso F; Soro S; Alcaro S; Tramontano A; Botta M
FEBS J; 2006 Jul; 273(14):3301-10. PubMed ID: 16803461
[TBL] [Abstract][Full Text] [Related]
11. Delineating the interaction of combretastatin A-4 with αβ tubulin isotypes present in drug resistant human lung carcinoma using a molecular modeling approach.
Kumbhar BV; Bhandare VV; Panda D; Kunwar A
J Biomol Struct Dyn; 2020 Feb; 38(2):426-438. PubMed ID: 30831055
[TBL] [Abstract][Full Text] [Related]
12. Microtubule alterations and mutations induced by desoxyepothilone B: implications for drug-target interactions.
Verrills NM; Flemming CL; Liu M; Ivery MT; Cobon GS; Norris MD; Haber M; Kavallaris M
Chem Biol; 2003 Jul; 10(7):597-607. PubMed ID: 12890533
[TBL] [Abstract][Full Text] [Related]
13. Structural insight into epothilones antitumor activity based on the conformational preferences and tubulin binding modes of epothilones A and B obtained from molecular dynamics simulations.
Jiménez VA; Alderete JB; Navarrete KR
J Biomol Struct Dyn; 2015; 33(4):789-803. PubMed ID: 24773261
[TBL] [Abstract][Full Text] [Related]
14. Elucidation of the anticancer potential and tubulin isotype-specific interactions of β-sitosterol.
Pradhan M; Suri C; Choudhary S; Naik PK; Lopus M
J Biomol Struct Dyn; 2018 Jan; 36(1):195-208. PubMed ID: 27960611
[TBL] [Abstract][Full Text] [Related]
15. A unified and quantitative receptor model for the microtubule binding of paclitaxel and epothilone.
Wang M; Xia X; Kim Y; Hwang D; Jansen JM; Botta M; Liotta DC; Snyder JP
Org Lett; 1999 Jul; 1(1):43-6. PubMed ID: 10822530
[TBL] [Abstract][Full Text] [Related]
16. Taxol allosterically alters the dynamics of the tubulin dimer and increases the flexibility of microtubules.
Mitra A; Sept D
Biophys J; 2008 Oct; 95(7):3252-8. PubMed ID: 18621813
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of beta-tubulin (Asp26Glu) and less stable microtubules.
Hari M; Loganzo F; Annable T; Tan X; Musto S; Morilla DB; Nettles JH; Snyder JP; Greenberger LM
Mol Cancer Ther; 2006 Feb; 5(2):270-8. PubMed ID: 16505100
[TBL] [Abstract][Full Text] [Related]
18. Molecular dynamic simulations of the tubulin-human gamma synuclein complex: structural insight into the regulatory mechanism involved in inducing resistance against Taxol.
Panneerselvam M; Muthu K; Jayaraman M; Sridharan U; Jenardhanan P; Ramadas K
Mol Biosyst; 2013 Jun; 9(6):1470-88. PubMed ID: 23532302
[TBL] [Abstract][Full Text] [Related]
19. Interaction of microtubule depolymerizing agent indanocine with different human αβ tubulin isotypes.
Kumbhar BV; Panda D; Kunwar A
PLoS One; 2018; 13(3):e0194934. PubMed ID: 29584771
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanism of action of microtubule-stabilizing anticancer agents.
Prota AE; Bargsten K; Zurwerra D; Field JJ; Díaz JF; Altmann KH; Steinmetz MO
Science; 2013 Feb; 339(6119):587-90. PubMed ID: 23287720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
